Raloxifene as a treatment option for viral infections.
Antiviral Agents
/ therapeutic use
Drug Repositioning
Estrogen Antagonists
/ therapeutic use
Estrogens
/ agonists
Humans
Molecular Docking Simulation
Osteoporosis, Postmenopausal
/ drug therapy
Raloxifene Hydrochloride
/ therapeutic use
SARS-CoV-2
/ drug effects
Selective Estrogen Receptor Modulators
/ therapeutic use
COVID-19 Drug Treatment
COVID-19
SARS-CoV-2
SERM
drug repositioning
estrogen receptor
raloxifene
Journal
Journal of microbiology (Seoul, Korea)
ISSN: 1976-3794
Titre abrégé: J Microbiol
Pays: Korea (South)
ID NLM: 9703165
Informations de publication
Date de publication:
Feb 2021
Feb 2021
Historique:
received:
25
11
2020
accepted:
28
12
2020
revised:
28
12
2020
entrez:
2
2
2021
pubmed:
3
2
2021
medline:
9
2
2021
Statut:
ppublish
Résumé
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused corona virus disease 2019 (COVID-19) pandemic and led to mass casualty. Even though much effort has been put into development of vaccine and treatment methods to combat COVID-19, no safe and efficient cure has been discovered. Drug repurposing or drug repositioning which is a process of investigating pre-existing drug candidates for novel applications outside their original medical indication can speed up the drug development process. Raloxifene is a selective estrogen receptor modulator (SERM) that has been approved by FDA in 1997 for treatment and prevention of postmenopausal osteoporosis and cancer. Recently, raloxifene demonstrates efficacy in treating viral infections by Ebola, influenza A, and hepatitis C viruses and shows potential for drug repurposing for the treatment of SARS-CoV-2 infection. This review will provide an overview of raloxifene's mechanism of action as a SERM and present proposed mechanisms of action in treatment of viral infections.
Identifiants
pubmed: 33527314
doi: 10.1007/s12275-021-0617-7
pii: 10.1007/s12275-021-0617-7
pmc: PMC7849956
doi:
Substances chimiques
Antiviral Agents
0
Estrogen Antagonists
0
Estrogens
0
Selective Estrogen Receptor Modulators
0
Raloxifene Hydrochloride
4F86W47BR6
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
124-131Références
J Clin Oncol. 2008 Sep 1;26(25):4151-9
pubmed: 18757329
Endocrinology. 1994 Nov;135(5):2001-5
pubmed: 7956922
J Amino Acids. 2011;2011:812540
pubmed: 22312471
Open Orthop J. 2009 Feb 20;3:14-21
pubmed: 19516920
Eur J Clin Pharmacol. 2020 Dec;76(12):1623-1630
pubmed: 32696234
J Clin Invest. 2020 Dec 1;130(12):6218-6221
pubmed: 32976118
J Clin Endocrinol Metab. 2004 Dec;89(12):6097-9
pubmed: 15579764
Nature. 2020 Jun;582(7813):469
pubmed: 32546811
Nat Rev Microbiol. 2019 Oct;17(10):593-606
pubmed: 31341272
Clin Exp Med. 2020 Nov;20(4):493-506
pubmed: 32720223
Science. 1996 Aug 30;273(5279):1222-5
pubmed: 8703055
Liver Int. 2003 Feb;23(1):63-9
pubmed: 12640729
Mol Endocrinol. 1994 Jan;8(1):21-30
pubmed: 8152428
Lancet. 2019 Sep 28;394(10204):1159-1168
pubmed: 31474332
Travel Med Infect Dis. 2020 Sep - Oct;37:101844
pubmed: 32791213
Mol Cell Endocrinol. 2014 Jan 25;382(1):665-672
pubmed: 23954741
JAMA. 1999 Aug 18;282(7):637-45
pubmed: 10517716
JAMA. 2006 Jun 21;295(23):2727-41
pubmed: 16754727
Curr Top Med Chem. 2012;12(6):486-504
pubmed: 22242852
J Clin Invest. 2000 Nov;106(10):1203-4
pubmed: 11086020
Breast Cancer. 1998 Apr 25;5(2):99-106
pubmed: 11091634
Physiol Rev. 2007 Jul;87(3):905-31
pubmed: 17615392
Hepatology. 2004 Dec;40(6):1426-33
pubmed: 15565616
Lancet. 2003 Aug 9;362(9382):419-27
pubmed: 12927427
Cancer Res. 1987 Aug 1;47(15):4020-4
pubmed: 3607747
Nature. 2000 Aug 17;406(6797):747-52
pubmed: 10963602
Front Med (Lausanne). 2020 Aug 05;7:370
pubmed: 32850890
Lancet Infect Dis. 2020 Sep;20(9):995-996
pubmed: 32422197
Endocrinology. 1996 Oct;137(10):4139-44
pubmed: 8828469
J Pharmacopuncture. 2019 Dec;22(4):210-224
pubmed: 31970018
N Engl J Med. 2005 Oct 20;353(16):1711-23
pubmed: 16236742
Obstet Gynecol. 2000 Jan;95(1):95-103
pubmed: 10636510
J Natl Cancer Inst. 1999 Nov 3;91(21):1809-19
pubmed: 10547388
Sci Rep. 2017 Jan 24;7:41226
pubmed: 28117364
Nature. 1997 Oct 16;389(6652):753-8
pubmed: 9338790
Pharmacol Ther. 2018 Jun;186:1-24
pubmed: 29289555
Pharmacol Rev. 1998 Jun;50(2):151-96
pubmed: 9647865
N Engl J Med. 1997 Dec 4;337(23):1641-7
pubmed: 9385122
Drugs Context. 2020 May 22;9:
pubmed: 32547625
Eur J Cancer. 2008 Jan;44(1):30-8
pubmed: 18068350
Endocr Rev. 2007 Aug;28(5):521-74
pubmed: 17640948
Nutr Metab Cardiovasc Dis. 2020 Jul 24;30(8):1227-1235
pubmed: 32595085
N Engl J Med. 2003 Feb 13;348(7):618-29
pubmed: 12584371
Proc Natl Acad Sci U S A. 2020 Oct 27;117(43):26946-26954
pubmed: 33028676
Am J Physiol Lung Cell Mol Physiol. 2016 Mar 1;310(5):L415-25
pubmed: 26684252
Nat Rev Microbiol. 2021 Apr;19(4):272-282
pubmed: 33024309
BMB Rep. 2020 Mar;53(3):166-171
pubmed: 31964466
FEBS Open Bio. 2012 Aug 22;2:279-83
pubmed: 23650611
Cell. 1988 Oct 7;55(1):145-56
pubmed: 3167974
Drugs. 2000 Aug;60(2):379-411
pubmed: 10983739
JAMA. 1999 Jun 16;281(23):2189-97
pubmed: 10376571
J Hepatol. 2012 Dec;57(6):1186-92
pubmed: 22889955
Crit Rev Oncol Hematol. 2004 Apr;50(1):3-22
pubmed: 15094156
In Vivo. 2020 Sep-Oct;34(5):3027-3028
pubmed: 32871847
Biomed Pharmacother. 2020 Jul;127:110195
pubmed: 32361161
Cancer Sci. 2015 Apr;106(4):337-43
pubmed: 25611678
World J Emerg Surg. 2020 Apr 9;15(1):26
pubmed: 32272957
Am J Obstet Gynecol. 2000 Mar;182(3):568-74
pubmed: 10739509
Bone. 2003 Oct;33(4):522-32
pubmed: 14555255
J Am Coll Radiol. 2020 Jun;17(6):724-729
pubmed: 32304643
Cytokine Growth Factor Rev. 2020 Jun;53:43-52
pubmed: 32409230
Lancet. 2008 Mar 1;371(9614):760-70
pubmed: 18313505
Infez Med. 2020 Ahead of print Jun 1;28(2):153-165
pubmed: 32275257